

EQA round: AP2/23 - Antithrombotic Agents

Deadline: 15.9.2023

Setup: groups - measurement principle; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL					
Set 1																
(108) Apixaban	[µg/L]				37									37	36	97
Sample A1		66,8	5,6	8,3	37		CVP	66,8	2,2	25%	50,1	83,5		37	36	97
(2) Chromogenous substrat		66,5	5,5	8,3	35	0								35		
Other					2	0								2		
							2x 1									
Sample B1		287	16	5,6	37		CVP	287	6,5	25%	215	359		37	37	100
(2) Chromogenous substrat		286	16	5,6	35	0								35		
Other					2	0								2		
							2x 1									
Set 2																
(109) Dabigatran	[µg/L]				37									37	36	97
Sample A2		211	19	8,8	37		CVP	211	7,5	30%	147	275		37	37	100
(1) Coagulometer		215	22	10	25	0								25		
(2) Chromogenous substrat		203	9,8	4,8	12	0								12		
Sample B2		45,9	6,2	14	37		CVP	45,9	2,5	30%	32,1	59,7		37	36	97
(1) Coagulometer		46,9	5,1	11	25	0								25		
(2) Chromogenous substrat		43,5	6,6	15	12	0								12		
Set 3																
(110) Rivaroxaban	[µg/L]				43									43	41	95
Sample A3		286	22	7,7	43		CVP	286	8,2	25%	214	358		43	42	98
(2) Chromogenous substrat		286	23	7,9	41	0								41		
Other					2	0								2		
							2x 1									
Sample B3		78,4	6,1	7,8	43		CVP	78,4	2,3	25%	58,8	98		43	41	95
(2) Chromogenous substrat		78	5,8	7,5	41	0								41		
Other					2	0								2		
							2x 1									